Evidence map›Paper›PMID 38064231›Full record

ArticleThe Journal of asthma : official journal of the Association for the Care of Asthma2024

The role of ACT score in mepolizumab discontinuation.

Neha Solanki, Brittany Beck, Monica Labadia, Kevin Smith, Laura Peterson, Stephanie King, Sarah Micklewright, Emily Pennington, Sobia Farooq, Peng Zhang and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of asthma : official journal of the Association for the Care of Asthma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Neha SolankiRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Brittany BeckLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Monica LabadiaLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Kevin SmithLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Laura PetersonLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Stephanie KingRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Sarah MicklewrightRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Emily PenningtonRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Sobia FarooqRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Peng ZhangRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Mark AronicaRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Joe ZeinRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Sumita KhatriNational Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
Suzy ComhairLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Serpil ErzurumRespiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · USNational Heart Lung and Blood Institute · US

Funding

Targeting pathological hyaluronan matricesP01HL103453 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2011 to 2020
$26.8M
Tissue Processing and Cell Culture COreP01HL081064 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI STUEHR, DENNIS J · 2006 to 2019
$17.8M
NHLBI NIH HHS P01 HL081064NHLBI NIH HHS P01 HL103453
6 · The paper itself

Abstract

backgroundMepolizumab is a therapy for severe asthma. We have little knowledge of the characteristics of people in the US that discontinue mepolizumab in clinical care.

objectiveTo investigate the real-world efficacy and time to clinical discontinuation of mepolizumab, we evaluated individuals with asthma started on mepolizumab at the Cleveland Clinic. We hypothesized that individuals that discontinue mepolizumab have more severe and uncontrolled asthma at baseline.

methodsBetween 2016 and 2022, patients who started on mepolizumab consented to be assessed over 18 months. At baseline, a questionnaire including demographic and medical history was collected. Laboratory findings such as ACT score, F

resultsGroup B [

conclusionIn this real-world study, we find that high eosinophil count may not be adequate in screening which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.

Indexed as

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaSeverity of Illness IndexAdultAgedFemaleHumansMaleMiddle AgedWithholding TreatmentAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedmepolizumabAsthmaasthma controlmepolizumab

Identifiers

PMID38064231
PMCPMC11076164
OpenAlexW4389477421

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.